close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

36.61 +0.58 (+1.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
From Veracyte, Inc.
Via Business Wire
Rising Cases of Early-Onset Colorectal Cancer Calls for Expanded Biotech Screening Methods
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – December 1, 2021 – Early onset colorectal cancer is currently on the rise [[1]], according to a new study [[2]] from the... 
Via FinancialNewsMedia
News headline image
Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Third Quarter 2021 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
From Veracyte, Inc.
Via Business Wire
News headline image
New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
From Veracyte, Inc.
Via Business Wire
News headline image
Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
News headline image
New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
From Veracyte, Inc.
Via Business Wire
News headline image
New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment
From Veracyte, Inc.
Via Business Wire
News headline image
New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Completes Acquisition of HalioDx
From Veracyte
Via Business Wire
News headline image
Veracyte Announces Second Quarter 2021 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today